New lung cancer drug

The European Commission recently granted marketing authorisation for necitumumab (Portrazza) for certain patients with non-small cell lung cancer (NSCLC).

Necitumumab is approved in combination with gemcitabine and cisplatin for adults with locally advanced or metastatic squamous NSCLC that expresses epidermal growth factor receptors, provided patients have not previously received chemotherapy for this condition. Manufacturer Eli Lilly says necitumumab is the first biologic licensed in the EU as a first-line treatment in this indication.

Recommended

Clinical review: Antihypertensive medication

NICE recommends Tremfya




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.